scholarly journals Prevalence and incidence of young onset dementia and associations with comorbidities: A study of data from the French national health data system

PLoS Medicine ◽  
2021 ◽  
Vol 18 (9) ◽  
pp. e1003801
Author(s):  
Laure Carcaillon-Bentata ◽  
Cécile Quintin ◽  
Marjorie Boussac-Zarebska ◽  
Alexis Elbaz

Background Dementia onset in those aged <65 years (young onset dementia, YOD) has dramatic individual and societal consequences. In the context of population aging, data on YOD are of major importance to anticipate needs for planning and allocation of health and social resources. Few studies have provided precise frequency estimates of YOD. The aim of this study is to provide YOD prevalence and incidence estimates in France and to study the contribution of comorbidities to YOD incidence. Methods and findings Using data from the French national health data system (Système National des Données de Santé, SNDS) for 76% of the French population aged 40 to 64 years in 2016 (n = 16,665,795), we identified all persons with dementia based on at least 1 of 3 criteria: anti-Alzheimer drugs claims, hospitalization with the International Classification of Diseases-10th Revision (ICD-10) dementia code (F00 to F03, G30, G31.0, G31.1, or F05.1), or registration for free healthcare for dementia. We estimated prevalence rate (PR) and incidence rate (IR) and estimated the association of comorbidities with incident YOD. Sex differences were investigated. We identified 18,466 (PRstandardized = 109.7/100,000) and 4,074 incident (IRstandardized = 24.4/100,000 person-years) persons with prevalent and incident YOD, respectively. PR and IR sharply increased with age. Age-adjusted PR and IR were 33% (95% confidence interval (CI) = 29 to 37) and 39% (95% CI = 31 to 48) higher in men than women (p < 0.001 both for PR and IR). Cardio- and cerebrovascular, neurological, psychiatric diseases, and traumatic brain injury prevalence were associated with incident YOD (age- and sex-adjusted p-values <0.001 for all comorbidities examined, except p = 0.109 for antihypertensive drug therapy). Adjustment for all comorbidities explained more than 55% of the sex difference in YOD incidence. The lack of information regarding dementia subtypes is the main limitation of this study. Conclusions We estimated that there were approximately 24,000 and approximately 5,300 persons with prevalent and incident YOD, respectively, in France in 2016. The higher YOD frequency in men may be partly explained by higher prevalence of cardiovascular and neurovascular diseases, substance abuse disorders, and traumatic brain injury and warrants further investigation.

2014 ◽  
Vol 75 (3) ◽  
pp. 339-341 ◽  
Author(s):  
Raquel C. Gardner ◽  
Kristine Yaffe

2014 ◽  
Vol 75 (3) ◽  
pp. 374-381 ◽  
Author(s):  
Peter Nordström ◽  
Karl Michaëlsson ◽  
Yngve Gustafson ◽  
Anna Nordström

2021 ◽  
Vol 27 (S1) ◽  
pp. i42-i48
Author(s):  
Barbara A Gabella ◽  
Jeanne E Hathaway ◽  
Beth Hume ◽  
Jewell Johnson ◽  
Julia F Costich ◽  
...  

BackgroundIn 2016, the CDC in the USA proposed codes from the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) for identifying traumatic brain injury (TBI). This study estimated positive predictive value (PPV) of TBI for some of these codes.MethodsFour study sites used emergency department or trauma records from 2015 to 2018 to identify two random samples within each site selected by ICD-10-CM TBI codes for (1) intracranial injury (S06) or (2) skull fracture only (S02.0, S02.1-, S02.8-, S02.91) with no other TBI codes. Using common protocols, reviewers abstracted TBI signs and symptoms and head imaging results that were then used to assign certainty of TBI (none, low, medium, high) to each sampled record. PPVs were estimated as a percentage of records with medium-certainty or high-certainty for TBI and reported with 95% confidence interval (CI).ResultsPPVs for intracranial injury codes ranged from 82% to 92% across the four samples. PPVs for skull fracture codes were 57% and 61% in the two university/trauma hospitals in each of two states with clinical reviewers, and 82% and 85% in the two states with professional coders reviewing statewide or nearly statewide samples. Margins of error for the 95% CI for all PPVs were under 5%.DiscussionICD-10-CM codes for traumatic intracranial injury demonstrated high PPVs for capturing true TBI in different healthcare settings. The algorithm for TBI certainty may need refinement, because it yielded moderate-to-high PPVs for records with skull fracture codes that lacked intracranial injury codes.


2018 ◽  
Vol 47 (7) ◽  
pp. 299-307 ◽  
Author(s):  
Clara Piffaretti ◽  
Vincent Looten ◽  
Sylvie Rey ◽  
Jeanne Fresson ◽  
Anne Fagot-Campagna ◽  
...  

Author(s):  
Peter B Walker ◽  
Melissa L Mehalick ◽  
Amanda C Glueck ◽  
Anna E Tschiffely ◽  
Craig A Cunningham ◽  
...  

Personalized medicine is a ubiquitous term that has come to be used to describe a medical model that proposes the customization of healthcare, such that decisions and/or treatments are tailored to each individual patient. Under this type of clinical practice model, diagnostic and prognostic decisions are often based upon selecting the most appropriate therapy based on a patient’s genetic, demographic, and/or other pertinent information. The primary aim of this paper is to use a personalized medicine framework to better understand the relationship between neuropsychological testing and the progression of symptoms in a blast-induced mild Traumatic Brain Injury (mTBI) patient population. In this paper, we extended our earlier work on Constrained Spectral Partitioning (CSP), a graph-based approach that incorporates additional information from separate graphs to help improve the clustering quality on both graphs simultaneously. While our previous work demonstrated the effectiveness of this algorithm in its ability to accurately classify whether symptoms improved or declined over time, that work did not provide any insights into the progression of symptoms. Therefore, this paper sought to identify, from a clinical perspective, whether symptoms increased/decreased over time. To accomplish this, we developed a decision tree classifier to classify symptom progression based on the outputs from our CSP algorithm. We present results from four separate decision tree classifiers that illustrate the adaptability of these algorithms for utilization as decision rules for the treatment of patients following blast-induced mTBI. Decision tree classifier models are useful in the healthcare setting because patient health data (e.g., diagnosis of a condition or a type of treatment) can be imput into the model and, based on the health data variables, a resulting outcome can be suggested, and providers can use this outcome as information to direct their clinical treatment.


2019 ◽  
Vol 8 (5) ◽  
pp. 686
Author(s):  
Dorji Harnod ◽  
Tomor Harnod ◽  
Cheng-Li Lin ◽  
Chia-Hung Kao

We used the National Health Insurance Research Database of Taiwan to determine whether patients with posttraumatic dementia (PTD) exhibit increased mortality and medical burden than those without it. Patients ≥20 years of age having head injury admission (per the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes 850–854, 959.01) between 2000 and 2012 were enrolled as traumatic brain injury (TBI) cohort. A PTD cohort (with ICD-9-CM codes 290, 294.1, 331.0) and a posttraumatic nondementia (PTN) cohort were established and compared in terms of age, sex, and comorbidities. We calculated adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) of all-cause mortality risk, number of hospital days, and frequency of medical visits in these cohorts. Patients with PTD had a higher mortality rate than did patients with TBI alone (rate per 1000 person-years: 12.00 vs. 6.32), with an aHR of 1.54 (95% CI: 1.32–1.80). Patients with PTD who were aged ≥65 years (aHR = 1.54, 95% CI: 1.31–1.80) or male (aHR = 1.78, 95% CI: 1.45–2.18) exhibited greatly increased risks of mortality. Furthermore, patients with PTD had 19.9 more hospital days and required medical visits 4.49 times more frequently compared with the PTN cohort. Taiwanese patients with PTD had increased mortality risk and medical burden compared with patients who had TBI only. Our findings provide crucial information for clinicians and the government to improve TBI and PTD outcomes.


Epidemiology ◽  
2018 ◽  
Vol 29 (6) ◽  
pp. 876-884 ◽  
Author(s):  
Oliver Lasry ◽  
Nandini Dendukuri ◽  
Judith Marcoux ◽  
David L. Buckeridge

Sign in / Sign up

Export Citation Format

Share Document